Bristol Myers first-quarter earnings miss expectations as cancer drugs underperform

Bristol Myers Squibb Co (BMY.N) reported lower-than-expected first-quarter profit on Thursday as sales of its high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.